Abstract: The present invention is directed to nanoparticulate compositions comprising meloxicam. The meloxicam particles of the composition have an effective average particle size of less than about 2000 nm.

Abstract: There invention discloses aqueous dispersions of nanoparticulate aerosol formulations, dry powder nanoparticulate aerosol formulation, propellant-based aerosol formulations, methods of using the formulations in aerosol delivery devices, and methods of making such formulations. The nanoparticles of the aqueous dispersions or dry powder formulations comprise insoluble drug particles having a surface modifier on the surface thereof.

Abstract: The present invention is directed to a method of milling small quantities of one or more candidate compounds to reduce the particle size of at least one candidate compound to about 2 microns or less. The apparatus used for the milling process can be one or more multi-well plates, or any other suitable apparatus. The resultant products are dispersions of nanoparticulate candidate compounds. The method is particularly suited for increasing the effectiveness of high throughput screening (“HTS”).

Abstract: The invention is directed to nanoparticulate triamcinolone and/or triamcinolone derivative compositions. The triamcinolone or triamcinolone derivative particles of the composition have an effective average particle size of less than about 2 microns.

Abstract: The present invention is directed to nanoparticulate compositions comprising benzoyl peroxide. The benzoyl peroxide particles of the composition have an effective average particle size of less than about 2 microns.

Abstract: The present invention is directed to nanoparticulate compositions comprising one or more sterols or stanols, such as sitosterol or phytosterol. The sterol particles of the composition have an effective average particle size of less than about 2000 nm. In another aspect of this invention, novel combinations of sterols and other cholesterol lowering agents are described and methods of using same are taught.

Abstract: Disclosed are in vitro methods for evaluating the in vivo redispersibility of dosage forms of poorly water-soluble active agents. The methods utilize media representative of in vivo human physiological conditions.

Abstract: The present invention is directed to nanoparticulate compositions comprising one or more polycosanols. The polycosanol particles of the composition have an effective average particle size of less than about 2000 nm. In another aspect of this invention, novel combinations of polycosanols and other cholesterol lowering agents are described and methods of using same are taught.

Abstract: Disclosed are compositions exhibiting a combination of immediate release and controlled release characteristics. The compositions comprise at least one poorly soluble active ingredient having a nanoparticulate particle size, at least one surface stabilizer adsorbed onto the surface of the nanoparticulate active agent particles, and at least one active ingredient having a microparticulate particle size.

Abstract: Bioadhesive nanoparticulate compositions, comprising active agent particles and one or more cationic surface stabilizers, are described. The cationic surface stabilizers prevent aggregation of the nanoparticles and increase bioadhesion of the nanoparticles to biological substrates, such as an insect, teeth, bone, nails, chitin, feathers, scales, mucous, skin, hair, plant tissue, etc. The particles may consist of pharmacologically active compounds (e.g., drug compounds for human or veterinary use), agricultural chemicals (pesticides, herbicides, fertilizers, and the like), cosmetic agents, consumer products (coloring agents, flavors, or fragrances), or other materials which function by interacting with biological substrates. In addition, the invention relates to methods of preparing and using such bioadhesive nanoparticulate compositions.

Abstract: Bioadhesive nanoparticulate compositions, comprising active agent particles and one or more cationic surface stabilizers, are described. The cationic surface stabilizers prevent aggregation of the nanoparticles and increase bioadhesion of the nanoparticles to biological substrates, such as an insect, teeth, bone, nails, chitin, feathers, scales, mucous, skin, hair, plant tissue, etc. The particles may consist of pharmacologically active compounds (e.g., drug compounds for human or veterinary use), agricultural chemicals (pesticides, herbicides, fertilizers, and the like), cosmetic agents, consumer products (coloring agents, flavors, or fragrances), or other materials which function by interacting with biological substrates. In addition, the invention relates to methods of preparing and using such bioadhesive nanoparticulate compositions.

Abstract: There invention discloses aqueous dispersions of nanoparticulate aerosol formulations, dry powder nanoparticulate aerosol formulation, propellant-based aerosol formulations, methods of using the formulations in aerosol delivery devices, and methods of making such formulations. The nanoparticles of the aqueous dispersions or dry powder formulations comprise insoluble drug particles having a surface modifier on the surface thereof.

Abstract: Bioadhesive nanoparticulate compositions, comprising active agent particles and one or more cationic surface stabilizers, are described. The cationic surface stabilizers prevent aggregation of the nanoparticles and increase bioadhesion of the nanoparticles to biological substrates, such as an insect, teeth, bone, nails, chitin, feathers, scales, mucous, skin, hair, plant tissue, etc. The particles may consist of pharmacologically active compounds (e.g., drug compounds for human or veterinary use), agricultural chemicals (pesticides, herbicides, fertilizers, and the like), cosmetic agents, consumer products (coloring agents, flavors, or fragrances), or other materials which function by interacting with biological substrates. In addition, the invention relates to methods of preparing and using such bioadhesive nanoparticulate compositions.

Abstract: A linear block copolymer comprising units of an alkylene oxide, linked to units of peptide via a linking group comprising a --CH.sub.2 CHOHCH.sub.2 N(R)-- moiety, is useful as an imaging agent, drug, prodrug or as a delivery system for imaging agents, drugs or prodrugs.

Abstract: There is disclosed a pharmaceutical composition which gels at physiological temperature. The composition is comprised of a block copolymer containing one or more polyoxyethylene blocks and one or more polyoxy (higher alkylene) blocks wherein at least some of the blocks are linked together by a linking group characterised in that the linking group is an oxymethylene group, and a therapeutic agent. The therapeutic agent is present as (i) nanoparticles of the therapeutic agent having the block copolymer adsorbed on the surface thereof, (ii) a suspension in a solution of the block copolymer, or (iii) as an aqueous solution in a solution of the block copolymer.

Abstract: Disclosed are contrast agents of the formula ##STR1## contained in aqueous compositions and methods for their use in diagnostic radiology of the gastrointestinal tract whereinZ=H, halo, C.sub.1 -C.sub.20 alkyl, cycloalkyl, lower alkoxy, cyano, where the alkyl and cycloalkyl groups can be substituted with halogen or halo-lower-alkyl groups;R=C.sub.1 -C.sub.25 alkyl, cycloalkyl, or halo-lower-alkyl, optionally substituted with halo, fluoro-lower-alkyl, aryl, lower-alkoxy, hydroxy, carboxy, lower-alkoxy carbonyl or lower-alkoxy-carbonyloxy, (CR.sub.1 R.sub.2).sub.p --(CR.sub.3 .dbd.CR.sub.4).sub.m Q, or (CR.sub.1 R.sub.2).sub.p --C.tbd.C--Q;R.sub.1, R.sub.2, R.sub.3 and R.sub.4 are independently lower-alkyl, optionally substituted with halo;x is 1-4;n is 1-5;m is 1-15;p is 1-10; andQ is H, lower-alkyl, lower-alkenyl, lower-alkynyl, lower-alkylene, aryl, or aryl-lower alkyl.

Abstract: A linear block copolymer comprising units of an alkylene oxide, linked to units of peptide via a linking group comprising a --CH.sub.2 CHOHCH.sub.2 N(R)-- moiety, is useful as an imaging agent, drug, prodrug or as a delivery system for imaging agents, drugs or prodrugs.

Abstract: Nanoparticulate crystalline therapeutic substances formulated with stabilizers and pharmaceutically acceptable clays to enhance contact between the crystalline therapeutic substances and the gastrointestinal tract and to provide extended therapeutic effect.

Abstract: There is disclosed a composition containing nanoparticles having a surface modifier wherein the surface modifier is a block copolymer containing one or more polyoxyethylene blocks and one or more polyoxy(higher alkylene) blocks wherein at least some of the blocks are linked together by a linking group characterized in that the linking group is an oxymethylene group.

Abstract: Disclosed are x-ray contrast compositions for oral or retrograde examination of the gastrointestinal tract comprising iodophenoxy alkanes and iodophenyl ethers as the x-ray producing agents in combination with a pharmaceutically acceptable clay in a pharmaceutically acceptable carrier; and methods for their use in diagnostic radiology of the gastrointestinal tract.